Diagnosis and Treatment > Medication

You are looking at 1 - 2 of 2 items for :

  • Doxorubicin x
Clear All
Impana Shetty Pediatric Oncology Branch, Rare Tumor Initiative, Center for Cancer Research, National Cancer Institute, Clinical Center

Search for other papers by Impana Shetty in
Google Scholar
PubMed
Close
,
Sarah Fuller Pediatric Oncology Branch, Rare Tumor Initiative, Center for Cancer Research, National Cancer Institute, Clinical Center

Search for other papers by Sarah Fuller in
Google Scholar
PubMed
Close
,
Margarita Raygada Pediatric Oncology Branch, Rare Tumor Initiative, Center for Cancer Research, National Cancer Institute, Clinical Center

Search for other papers by Margarita Raygada in
Google Scholar
PubMed
Close
,
Maria J Merino Laboratory of Pathology, National Cancer Institute, Clinical Center

Search for other papers by Maria J Merino in
Google Scholar
PubMed
Close
,
B J Thomas Pediatric Oncology Branch, Rare Tumor Initiative, Center for Cancer Research, National Cancer Institute, Clinical Center

Search for other papers by B J Thomas in
Google Scholar
PubMed
Close
,
Brigitte C Widemann Pediatric Oncology Branch, Rare Tumor Initiative, Center for Cancer Research, National Cancer Institute, Clinical Center

Search for other papers by Brigitte C Widemann in
Google Scholar
PubMed
Close
,
Karlyne M Reilly Pediatric Oncology Branch, Rare Tumor Initiative, Center for Cancer Research, National Cancer Institute, Clinical Center

Search for other papers by Karlyne M Reilly in
Google Scholar
PubMed
Close
,
Karel Pacak Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA

Search for other papers by Karel Pacak in
Google Scholar
PubMed
Close
, and
Jaydira Del Rivero Pediatric Oncology Branch, Rare Tumor Initiative, Center for Cancer Research, National Cancer Institute, Clinical Center

Search for other papers by Jaydira Del Rivero in
Google Scholar
PubMed
Close

Summary

Adrenocortical carcinoma (ACC) is an aggressive cancer that originates in the cortex of the adrenal gland and generally has a poor prognosis. ACC is rare but can be more commonly seen in those with cancer predisposition syndromes (e.g. Li-Fraumeni and Lynch Syndrome). The diagnosis of ACC is sometimes uncertain and it requires the use of precise molecular pathology; the differential diagnosis includes pheochromocytoma, adrenal adenoma, renal carcinoma, or hepatocellular carcinoma. We describe a case of a 57-year-old woman with Lynch Syndrome and metastatic ACC who was initially diagnosed as having pheochromocytoma. The tumor was first identified at 51 years of age by ultrasound followed by a CT scan. She underwent a left adrenalectomy, and the histopathology identified pheochromocytoma. Two years later, she had tumor recurrence with imaging studies showing multiple lung nodules. Following a wedge resection by video-assisted thoracoscopic surgery (VATS), histopathology was read as metastatic pheochromocytoma at one institution and metastatic ACC at another institution. She later presented to the National Institutes of Health (NIH) where the diagnosis of ACC was confirmed. Following her ACC diagnosis, she was treated with mitotane and pembrolizumab which were stopped due to side effects and progression of disease. She is currently receiving etoposide, doxorubicin, and cisplatin (EDP). This case highlights the importance of using a multi-disciplinary approach in patient care. Thorough evaluation of the tumor’s pathology and analysis of the patient’s genetic profile are necessary to obtain the correct diagnosis for the patient and can significantly influence the course of treatment.

Learning points:

  • Making the diagnosis of ACC can be difficult as the differential diagnosis includes pheochromocytoma, adrenal adenoma, renal carcinoma, or hepatocellular carcinoma.

  • Patients with Lynch Syndrome should undergo surveillance for ACC as there is evidence of an association between Lynch Syndrome and ACC.

  • Conducting a complete tumor immunoprofile and obtaining a second opinion is very important in cases of suspected ACC in order to confirm the proper diagnosis.

  • A multi-disciplinary approach including genetic testing and a thorough evaluation of the tumor’s pathology is imperative to ensuring that the patient receives an accurate diagnosis and the appropriate treatment.

Open access
Carine Ghassan Richa Department of Endocrinology, Mount Lebanon Hospital, Beirut, Lebanon
Lebanese University, Hadath, Lebanon

Search for other papers by Carine Ghassan Richa in
Google Scholar
PubMed
Close
,
Khadija Jamal Saad Department of Endocrinology, Mount Lebanon Hospital, Beirut, Lebanon
Lebanese University, Hadath, Lebanon

Search for other papers by Khadija Jamal Saad in
Google Scholar
PubMed
Close
,
Georges Habib Halabi Department of Endocrinology, Mount Lebanon Hospital, Beirut, Lebanon
Mount Lebanon Hospital, Beirut, Lebanon

Search for other papers by Georges Habib Halabi in
Google Scholar
PubMed
Close
,
Elie Mekhael Gharios Department of Endocrinology, Mount Lebanon Hospital, Beirut, Lebanon
Mount Lebanon Hospital, Beirut, Lebanon

Search for other papers by Elie Mekhael Gharios in
Google Scholar
PubMed
Close
,
Fadi Louis Nasr Mount Lebanon Hospital, Beirut, Lebanon

Search for other papers by Fadi Louis Nasr in
Google Scholar
PubMed
Close
, and
Marie Tanios Merheb Department of Endocrinology, Mount Lebanon Hospital, Beirut, Lebanon
Mount Lebanon Hospital, Beirut, Lebanon

Search for other papers by Marie Tanios Merheb in
Google Scholar
PubMed
Close

Summary

The objective of this study is to report three cases of paraneoplastic or ectopic Cushing syndrome, which is a rare phenomenon of the adrenocorticotropic hormone (ACTH)-dependent Cushing syndrome. Three cases are reported in respect of clinical presentation, diagnosis and treatment in addition to relevant literature review. The results showed that ectopic ACTH secretion can be associated with different types of neoplasm most common of which are bronchial carcinoid tumors, which are slow-growing, well-differentiated neoplasms with a favorable prognosis and small-cell lung cancer, which are poorly differentiated tumors with a poor outcome. The latter is present in two out of three cases and in the remaining one, primary tumor could not be localized, representing a small fraction of patients with paraneoplastic Cushing. Diagnosis is established in the setting of high clinical suspicion by documenting an elevated cortisol level, ACTH and doing dexamethasone suppression test. Treatment options include management of the primary tumor by surgery and chemotherapy and treating Cushing syndrome. Prognosis is poor in SCLC. We concluded that in front of a high clinical suspicion, ectopic Cushing syndrome diagnosis should be considered, and identification of the primary tumor is essential.

Learning points:

  • Learning how to suspect ectopic Cushing syndrome and confirm it among all the causes of excess cortisol.

  • Distinguish between occult and severe ectopic Cushing syndrome and etiology.

  • Providing the adequate treatment of the primary tumor as well as for the cortisol excess.

  • Prognosis depends on the differentiation and type of the primary malignancy.

Open access